Photo from Jason A. Mouabbi/Twitter
Sep 25, 2023, 15:17
Jason A. Mouabbi: Another ADC promises to broaden the treatment horizon in HR+ metastatic breast cancer.
Jason A. Mouabbi, Assistant Professor at MD Anderson Cancer Center, made the following post on X/Twitter:
“Exciting news! Another ADC promises to broaden the treatment horizon in HR+ metastatic breast cancer.
Questions swirling in my mind:
1. HER2-low dilemma: Dato-DXd or T-DXd first? Can sequential use with the same drug conjugate (Deruxtecan) yield promising results?
2. How to choose between Sacituzumab & Dato-DXd? Can we sequence them?
So many queries, so few answers!
Hoping for a prospective registry to track ADC sequencing and unveil solutions to these questions and more!”
For more information click here.
Source: Jason A. Mouabbi/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19